Join 60,000+ competitive exam aspirants
or with email
Your Cart
SubtotalтВ╣0
TotalтВ╣0
Examoogle тАв User тАв info@examoogle.com тАв EE-2024-8821
Chapter 1 of 12 тАв Page 1 of 248ЁЯФТ Protected PDF тАв Watermarked
Join 60,000+ competitive exam aspirants
Which country launched the first indigenous, Low-Cost Gene Therapy for Sickle Cell Disease, named "BIRSA 101"?
India
Japan
China
Spain
India
India has officially developed its first indigenous, low-cost gene therapy, known as BIRSA 101, for the treatment of Sickle Cell Disease. This medical breakthrough focuses on using advanced genetic engineering to modify hematopoietic stem cells, aiming to make life-saving therapy accessible to a larger patient population in India.
India has officially developed its first indigenous, low-cost gene therapy, known as BIRSA 101, for the treatment of Sickle Cell Disease. This medical breakthrough focuses on using advanced genetic engineering to modify hematopoietic stem cells, aiming to make life-saving therapy accessible to a larger patient population in India.
Think of it like a faulty software program in a computer; BIRSA 101 acts like a 'patch' that installs the correct, bug-free code into the system so the machine can run normally.
BIRSA: Bio-engineered Indian Remedy for Sickle-cell Anemia.
HbAтЖТNormal┬аHemoglobin
HbSтЖТSickle┬аCell┬аHemoglobin
Sickle Cell Disease is caused by a point mutation in the ╬▓-globin gene, leading to the production of abnormal hemoglobin HbS. BIRSA 101 utilizes a lentiviral vector-based gene therapy to introduce a functional copy of the ╬▓-globin gene into the patient's own hematopoietic stem cells ex vivo. Once these modified cells are transplanted back, they produce healthy hemoglobin, effectively bypassing the physiological consequences of the mutation.
Sickle Cell Disease is an autosomal recessive genetic disorder.
The mutation involves a substitution of Valine for Glutamic acid at the 6th position of the ╬▓-globin chain.
BIRSA 101 significantly reduces the financial burden compared to international gene therapies costing millions.
The therapy employs ex vivo genetic modification.
Significant cost reduction compared to global benchmarks.
Indigenous development ensures better alignment with Indian genetic diversity.
Curative potential rather than just symptom management.
Requires high-end technical infrastructure for stem cell handling.
Long-term efficacy studies are ongoing.
Accessibility requires specialized hematology centers.
Treatment of Sickle Cell Anemia patients in India.
Foundation for future gene therapies for other hereditary blood disorders.
Sickle cell disease is highly prevalent among tribal populations in India.
The government aims to eliminate sickle cell disease by 2047 through national screening and treatment programs.
Options B, C, and D are incorrect as they have not developed this specific indigenous product named BIRSA 101.
A is correct тАФ India has successfully pioneered the 'BIRSA 101' gene therapy as an affordable, indigenous solution to treat Sickle Cell Disease.
In competitive exams, always link 'Indigenous' breakthroughs in Biotechnology with the 'Make in India' or 'Atmanirbhar Bharat' initiatives for better recall.
Get instant step-by-step AI explanations, full shift Previous Year Papers (SSC GD, RRB, SSC JE), and regional rank analysis on the official Examoogle App.
Free Download тАв 100K+ Aspirants